drugset / Trial / NCT06954246
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
Timeline
- Start
- 2025-06-04
- Primary completion
- 2027-05
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Irinotecan | Small molecule | 65 mg/m2 | Intravenous |
| Subject | MHB088C | Monoclonal antibody | 2 mg/kg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Comparator | Topotecan | Small molecule | 1.25 mg/m2 | Intravenous |